

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: David A. Griffith :
APPLICATION NO.: 10/762,959 : Examiner: Thomas C. McKenzie
FILING DATE: January 21, 2004 : Group Art Unit: 1625
TITLE: Cannabinoid Receptor Ligands and Uses Thereof :
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

A final Office Action on the merits has not been received; therefore, a fee for this Supplemental Information Disclosure Statement is required. Please charge the appropriate fee to Deposit Account No. 16-1445.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached from PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Date: July 3, 2006

Respectfully submitted,

Arlene K. Musser
Arlene K. Musser
Attorney for Applicant(s)
Reg. No. 37,895

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0871

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO. PC25408A				SERIAL NO. 10/762,959				
				APPLICANT David A. Griffith								
				FILING DATE January 21, 2004				GROUP 1625				
U.S. PATENT DOCUMENTS												
EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US	2004/0092520						5/13/04	Griffith	514	242	
FOREIGN PATENT DOCUMENTS												
DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
												YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)												
		Beardsley, P.M., et al., <u>Behavioural Pharmacology</u> , "Current Evidence Supporting a Role of Cannabinoid CB1 Receptor (CB1R) Antagonists as Potential Pharmacotherapies for Drug Abuse Disorders", Vol. 16, pages 275-296 (2005)										
		Bermudez-Siva, F., et al., <u>Journal of Pharmacology</u> , "Activation of Cannabinoid CB1 Receptors Induces Glucose Intolerance in Rats", Vol. 531, pages 282-284 (2006)										
		Brittain, H.G., <u>Drugs and the Pharmaceutical Sciences</u> , "Polymorphism in Pharmaceutical Solids", Vol. 95, pages 202-207 (1999)										
		Brodie, B.B., <u>Life Sciences</u> , "Rimonabant: The First Therapeutically Relevant Cannabinoid Antagonist", Vol. 77, pages 2339-2350 (2005)										
		Cao, X., et al., "A Selective Cannabinoid CB1 Antagonist Increases Levodopa Responses in Parkinsonian Monkeys"										
		Chambers, A.P., et al., <u>Physiology & Behavior</u> , "Cannabinoid (CB1) Receptor Antagonist, AM 251, causes a Sustained Reduction of Daily Food Intake in the Rat", Vol. 82, pages 863-869 (2004)										
		Chaperon, F., et al., <u>Psychopharmacology</u> , "Involvement of Central Cannabinoid (CB1) Receptors in the Establishment of Place Conditioning in Rats", Vol. 135, pages 324-332 (198)										
		Cohen, C., et al., <u>Behavioural Pharmacology</u> , "SR141716, A Central Cannabinoid (CB1) Receptor Antagonist, Blocks the Motivational and Dopamine-Releasing Effects of Nicotine in Rats", Vol. 13, pages 451-463 (2002)										
		Crocì, T., et al., <u>British Journal of Pharmacology</u> , "Role of Cannabinoid CB1 Receptors and Tumor Necrosis Factor - α in the Gut and Systemic Anti-Inflammatory Activity of SR 141716 (Rimonabant) in Rodents", Vol. 140, pages 115-122 (2003)										
		De Vries, T.J., et al., <u>TRENDS in Pharmacological Sciences</u> , "Cannabinoid CB1 Receptors Control Conditioned Drug Seeking", Vol. 26 No. 8, pages 420-426 (2005)										
		Di Marzo, V., <u>TRENDS in Pharmacological Sciences</u> , "A Brief History of Cannabinoid and Endocannabinoid Pharmacology as Inspired by the Work of British Scientists", Vol. 20 No. 20 pages 1-7 (2006)										
		Di Marzo, V., et al., <u>The FASEB Journal</u> , "Enhanced Levels of Endogenous Cannabinoids in the Globus Pallidus are Associated with a Reduction in Movement in an Animal Model of Parkinson's Disease", Vol. 14, pages 1432-1438 (2000)										
		Fernandez, J.R., et al., <u>Current Opinion in Investigational Drugs</u> , "Rimonabant Sanofi-Synthelabo", Vol. 5, No. 4, pages 430-435 (2004)										
		Ferrer, B., et al., <u>European Journal of Neuroscience</u> , "Effects of Levodopa on Endocannabinoid Levels in Rat Basal Ganglia: Implications for the Treatment of Levodopa-Induced Dyskinesias", Vol. 18, pages 1607-1614 (2003)										
		Griebel, G., et al., <u>Biol. Psychiatry</u> , "Effects of the Cannabinoid CB1 Receptor antagonist Rimonabant in Models of Emotional										

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC25408A	SERIAL NO. 10/762,959
		APPLICANT David A. Griffith	
		FILING DATE January 21, 2004	GROUP 1625
		Reactivity in Rodents", Vol. 57, pages 261-267 (2005)	
		Lange, J., et al., <u>Drug Discovery Today</u> "Medicinal Chemistry Strategies to CB1 Cannabinoid Receptor Antagonists", Vol. 10, No. 10, pages 693-702 (2005)	
		Le Foll, B., et al., <u>NeuroReport</u> , "Reimonabant, a CB1 Antagonist, Blocks Nicotine-Conditioned Place Preferences", Vol. 15, No. 13, pages 2139-2143 (2004)	
		Mansbach, R.S., et al., <u>Psychopharmacology</u> , "Effects of the Cannabinoid CB1 Receptor Antagonist SR141716A on the Behaviour of Pigeons and Rats", Vol. 124, pages 315-322 (1996)	
		Mas-Nieto, M., et al., <u>British Journal of Pharmacology</u> , "Reduction of Opioid Dependence by the CB1 antagonist SR141716A in Mice: Evaluation of the Interest in Pharmacology of Opioid Addiction", Vol. 132, pages 1809-1816 (2001)	
		Mechoulam, R., et al., <u>TRENDS in Pharmacological Sciences</u> , "Cannabis and Alcohol - A Close Friendship", Vol. 24, No. 6, pages 266-268 (2003)	
		Muccioli, G.G., et al., <u>Current Medicinal Chemistry</u> , "Current Knowledge on the Antagonists and Inverse Agonists of Cannabinoid Receptors", Vol. 12, pages 1361-1394 (2005)	
		Pagotto, U., et al., <u>Endocrine Reviews</u> , "The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance", Vol. 27, No. 1, pages 73-100 (2006)	
		Pagotto, U., et al., <u>Current Opinion in Endocrinology & Diabetes</u> , "the Role of the Endocannabinoid Pathway in Metabolism and Diabetes", Vol. 13, pages 171-178 (2006)	
		Poncelet, M., et al., <u>Psychopharmacology</u> , "Blockade of Cannabinoid (CB1) Receptors By SR 141716 Selectively Antagonizes Drug-Induced Reinstatement of Exploratory Behaviour in Gerbils", Vol. 144, pages 144-150 (1999)	
		Sanudo-Pena, M., et al., <u>Neuroscience Letters</u> , "Endogenous Cannabinoids As an Aversive or Counter-Rewarding System in the Rat", Vol. 223, pages 125-128 (1997)	
		Smith, R.A., et al., <u>IDrugs</u> , "Recent Advances in the Research and Development of CB1 Antagonists", Vol. 8, No. 1, pages 53-66 (2005)	
		Thakur, G.A., et al., <u>Mini-Reviews in Medicinal Chemistry</u> , "CB1 Cannabinoid Receptor Ligands", Vol. 5, pages 631-640 (2005)	
		Van Der Stelt, M., et al., <u>The FASEB Journal</u> , "A Role For Endocannabinoids in the Generation of Parkinsonism and Levodopa-Induced Dyskinesia in MPTP-Lesioned Non-Human Primate Models of Parkinson's Disease", Vol. 19, pages 1140-1142 (2005)	
		Van Gaal, L., et al., <u>Lancet</u> , "Effects of the Cannabinoid-1 Receptor Blocker Rimonabant on Weight Reduction and Cardiovascular Risk Factors in Overweight Patients: 1-year Experience from the RIO-Europe Study", Vol. 365, pages 1389-1397 (2005)	
		Witkin, J.M., et al., <u>TRENDS in Pharmacological Sciences</u> , "A Therapeutic Role for Cannabinoid CB1 Receptor Antagonists in Major Depressive Disorders", Vol. 26, No. 12, pages 609-617 (2005)	
		Wolff, M., et al., <u>European Journal of Pharmacology</u> , "SR141716A, A Cannabinoid CB1 Receptor Antagonist, Improves Memory in a Delayed Radial Maze Task", Vol. 477, pages 213-217 (2003)	
		Louis, C., et al., <u>Psychopharmacology</u> , "Surlinabant, a New CB1 Receptor Antagonist, Displays Efficacy in Animal Models of Attention Deficit/Hyperactivity Disorder", Vol. 30, S173, Abstract 77 (2005)	
EXAMINER		DATE CONSIDERED	